Cipher Pharmaceuticals Inc. (TSX:CPH)

Market Cap	422.20M +44.7%
Revenue (ttm)	69.17M +51.2%
Net Income	37.47M +136.7%
EPS	1.44 +128.3%
Shares Out	25.28M
PE Ratio	11.60
Forward PE	16.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,283
Average Volume	33,278
Open	16.47
Previous Close	16.70
Day's Range	16.25 - 16.74
52-Week Range	10.61 - 17.50
Beta	0.67
RSI	61.54
Earnings Date	Mar 12, 2026

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the manage...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: CPH

Financial Performance

In 2025, Cipher Pharmaceuticals's revenue was $50.45 million, an increase of 51.22% compared to the previous year's $33.36 million. Earnings were $27.33 million, an increase of 136.72%.

Financial numbers in USD